{{Rsnum
|rsid=915832
|Gene=PRDM15
|Chromosome=21
|position=41855386
|Orientation=plus
|GMAF=0.3159
|Gene_s=PRDM15
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 8.0 | 38.1 | 54.0
| HCB | 16.8 | 56.2 | 27.0
| JPT | 20.4 | 54.0 | 25.7
| YRI | 10.9 | 46.9 | 42.2
| ASW | 10.5 | 47.4 | 42.1
| CHB | 16.8 | 56.2 | 27.0
| CHD | 19.3 | 57.8 | 22.9
| GIH | 10.9 | 46.5 | 42.6
| LWK | 15.5 | 49.1 | 35.5
| MEX | 1.7 | 17.2 | 81.0
| MKK | 17.3 | 49.4 | 33.3
| TSI | 6.9 | 48.0 | 45.1
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23006423
  |Trait=Response to taxane treatment (placlitaxel)
  |Title=Genetic association with overall survival of taxane-treated lung cancer patients - A genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
  |RiskAllele=
  |Pval=7E-6
  |OR=NR
  |ORtxt=NR
  |OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}